Back to results
US 11,891,622 B2Granted
RPE cell populations and methods of generating same
AssigneeCell Cure Neurosciences Ltd.
InventorsOsnat Bohana-Kashtan, Lior Ann Rosenberg Belmaker, Ofer Wiser
Life of this patent
Estimating the term…
Abstract
A population of human polygonal RPE cells is disclosed. At least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms. Methods of generating same are also disclosed.
Claims17
A human retinal pigment epithelium (RPE) cell population for treatment of a retinal degenerative disease, comprising:
- an effective amount of in vitro differentiated human RPE cells to treat the retinal degenerative disease,
- wherein the human RPE cells are in suspension,
- wherein at least 95% of the human RPE cells co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), and
- wherein the human RPE cells have a ratio of apical secretion of pigment epithelium derived growth factor (PEDF):
- basal secretion of PEDF greater than 1 in a monolayer.
2 more elements
A human retinal pigment epithelium (RPE) cell population for treatment of a retinal degenerative disease comprising:
- about 50,000 to about 200,000 in vitro differentiated human RPE cells,
- wherein the RPE cells are in suspension,
- wherein at least 95% of the human RPE cells co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), and
- wherein the RPE cells have a ratio of apical secretion of pigment epithelium derived growth factor (PEDF):
- basal secretion of PEDF greater than 1 in a monolayer.
2 more elements
Dependencies are inferred from the claim text.